



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

DIVISION OF
MARKET REGULATION

March 2, 2007

Jeffrey M. Oakes
Davis Polk & Wardwell
99 Gresham Street
London EC2V 7NG
England

Re: Cash Tender Offer by Sulzer AG for the Ordinary Shares of Bodycote
International plc
TP No. 07-48

Dear Mr. Oakes:

In your letter dated March 2, 2007, as supplemented by conversations with the staff of the Division of Market Regulation ("Division"), you request exemptive relief from Rule 14e-5 under the Securities Exchange Act of 1934 ("Exchange Act") in connection with purchases and arrangements to purchase shares of Bodycote International plc by Sulzer AG and certain persons acting on its behalf following public announcement of the tender offer for the Ordinary Shares of Bodycote International plc.

As you note in your letter, the Securities and Exchange Commission ("Commission") has granted relief on numerous occasions, similar to that requested by you on behalf of Sulzer AG, with respect to other purchases and arrangements to purchase subject securities or related securities in accordance with local law during a tender offer.¹

Rule 14e-5 under the Exchange Act prohibits a covered person from directly or indirectly purchasing or arranging to purchase subject securities or any related securities except as part of the tender offer. This prohibition applies from the time the tender offer is publicly announced until it expires. Rule 14e-5 defines a covered person as (i) the offeror and its affiliates, (ii) the offeror's dealer-manager and its affiliates, (iii) any advisors to the parties described in (i) and (ii) above whose compensation is dependent on the completion of the offer and (iv) any person acting, directly or indirectly, in concert with any of the foregoing in connection with any purchase or arrangement to purchase any subject securities or any related securities.

¹ Rule 14e-5 does not explicitly include the term "exchange offer" as former Rule 10b-13 did because in Regulation 14E the term "tender offer" includes offers to exchange securities for cash and/or securities. The terms "subject securities" and "related securities" are defined in Rule 14e-5(c).

With regard to cross-border tender offers, local law of the target company jurisdiction may permit the offeror and its affiliates and/or agents to purchase subject securities or related securities outside of the tender offer under certain conditions. Application of Rule 14e-5 to such offers would prohibit such purchases where the purchases are outside of the tender offer and do not fall within any of the excepted activities specifically outlined in Rule 14e-5. Accordingly, in the absence of exemptive relief, such purchases would be prohibited after announcement of the offer notwithstanding the fact that such purchases are permitted under local law. Prohibition of such permitted purchases would run counter to the Commission's policy of encouraging issuers and bidders to extend tender and exchange offers, rights offerings and business combinations to the U.S. securityholders of foreign private issuers.²

Accordingly, we find that it is appropriate in the public interest and consistent with the protection of investors to grant, and hereby grant, an exemption from Rule 14e-5 under the Exchange Act to permit any "Prospective Purchaser"³ to purchase or arrange to purchase subject securities or any related security pursuant to a tender offer that meets the following conditions:

1. The company that is the target of the offer ("subject company") is a "foreign private issuer" as defined in Rule 3b-4(c) of the Exchange Act;
2. The offeror reasonably intends to rely on Tier II exemptive relief under Rule 14d-1(d) of the Exchange Act in connection with the tender offer;
3. The Prospective Purchasers comply with the applicable laws and regulations of the "home jurisdiction," as defined in Rule 14d-1;⁴
4. The laws of the home jurisdiction require that the tender offer price be increased to match any consideration paid outside of the tender offer that is greater than the tender offer price;⁵

² Cross-Border Tender and Exchange Offers, Business Combinations and Rights Offerings, Release No. 34-42054, International Series No. 1208 (October 26, 1999), Section II.C.1.

³ For purposes of our response, "Prospective Purchaser" refers to the offeror, its affiliates, and/or its agents. An "affiliate" is any person that directly or indirectly, through one or more intermediaries, controls, or is controlled by, or is under common control with, the offeror. An "agent" is any broker-dealer or financial advisor who acts on behalf of the offeror in an agency capacity to effect purchases of subject securities or related securities during the pendency, but outside, of the tender offer.

⁴ The term "home jurisdiction" is defined in the Instructions to paragraphs (c) and (d) of Rule 14d-1 as both the jurisdiction of the subject company's incorporation, organization or chartering and the principal foreign market where the subject company's securities are listed or quoted.

⁵ We note that raising the tender offer price may trigger obligations under Rules 13e-4(e)(3)(ii) and 14e-1(b), which requires that a tender offer remain open for at least ten business days following notice to security holders of an increase in the consideration offered. In addition, raising the tender offer price may give rise to amendment and dissemination requirements under applicable tender offer rules.

5. The Commission and the home jurisdiction are parties to a bilateral or multilateral memorandum of understanding (MOU) as to consultation and cooperation in the administration and enforcement of securities laws;⁶
6. No purchases or arrangements to purchase subject securities or related securities, otherwise than pursuant to the tender offer, are made in the United States;
7. The United States offering materials disclose prominently the possibility of, or the intention to make, purchases or arrangements to purchase subject securities or related securities outside of the tender offer by the Prospective Purchasers and disclose the manner in which information regarding such purchases or arrangements to purchase will be disseminated;
8. The Prospective Purchasers disclose in the United States, to the extent such information is made public in the home jurisdiction pursuant to applicable law, information regarding all purchases of subject securities or related securities otherwise than pursuant to the tender offer since the announcement date;
9. The Prospective Purchasers provide to the Division, upon request, a daily time-sequenced schedule of all purchases of subject securities or related securities made by the Prospective Purchasers from the announcement date until the tender offer expires, on a transaction-by-transaction basis, including:
 - a. size, broker (if any), time of execution, and price of purchase; and
 - b. the exchange, quotation system, or other facility through which the purchase occurred;
10. Upon the request of the Division, the Prospective Purchasers transmit the information as specified in paragraphs 9.a. and 9.b. above to the Division at its offices in Washington, D.C. within 30 days of its request;
11. The Prospective Purchaser retains all documents and other information required to be maintained pursuant to this exemption for a period of not less than two years from the date of the termination of the offer;
12. Representatives of the Prospective Purchasers are made available (in person at the offices of the Division in Washington, D.C. or by telephone) to respond to inquiries of the Division relating to their records; and

⁶ A list of jurisdictions with which the Commission has entered into bilateral MOUs is maintained on the Commission's Web site at http://www.sec.gov/about/offices/oia/oia_bilateral.htm. In addition, the Commission is party to the Multilateral Memorandum of Understanding Concerning Consultation and Cooperation and the Exchange of Information of the International Organization of Securities Commissions, dated May, 2002. Information concerning the Multilateral Memorandum of Understanding can be found at <http://www.iosco.org>.

Jeffrey M. Oakes, Esq.

March 2, 2007

Page 4

13. Except as otherwise exempted herein, the Prospective Purchasers must comply with Rule 14e-5.

This exemption is subject to modification or revocation if at any time the Commission or Division determines that such action is necessary or appropriate in furtherance of the purposes of the Exchange Act. In addition, persons relying on this exemption are directed to the anti-fraud and anti-manipulation provisions of the Exchange Act, particularly Sections 14(e), 10(b), and Rule 10b-5 thereunder. Responsibility for compliance with these and other provisions of the federal or state securities laws must rest with persons relying on this exemptive position. The staff expresses no view with respect to other questions that the proposed transactions may raise, including, but not limited to, the adequacy of disclosure concerning, and the applicability of other federal and state laws to, the proposed transactions.

For the Commission,
by the Division of Market Regulation
pursuant to delegated authority,



James A. Brigagliano
Associate Director
Division of Market Regulation

Attachment

DAVIS POLK & WARDWELL

450 LEXINGTON AVENUE
NEW YORK, N.Y. 10017

1300 I STREET, N.W.
WASHINGTON, D.C. 20005

1600 EL CAMINO REAL
MENLO PARK, CA 94025

15, AVENUE MATIGNON
75008 PARIS

99 GRESHAM STREET
LONDON EC2V 7NG
TELEPHONE 020 7 418 1300
FAX 020 7 418 1400

WRITER'S DIRECT
020 7418 1386

MESSETURM
60308 FRANKFURT AM MAIN

MARQUÉS DE LA ENSENADA, 2
28004 MADRID

1-6-1 ROPFONGI
MINATO-KU, TOKYO 106-6033

3A CHATER ROAD
HONG KONG

March 2, 2007

Re: **Possible Cash Offer by Sulzer AG for the Ordinary Shares of
Bodycote International plc**

James Brigagliano
Associate Director
Division of Market Regulation
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549

Dear Mr. Brigagliano:

We are writing on behalf of our client, Sulzer AG, a stock corporation limited by shares organized under the laws of Switzerland ("Sulzer"). As described in more detail in this letter, Sulzer is considering commencing a cash tender offer (the "Offer") for all of the issued and to be issued ordinary shares, nominal value 10 pence sterling per share (the "Bodycote Shares"), of Bodycote International plc, a public limited company incorporated under the laws of England and Wales ("Bodycote").

We hereby request that the staff (the "Staff") of the Securities and Exchange Commission (the "Commission") grant exemptive relief from Rule 14e-5 under the Securities Exchange Act of 1934, as amended (the "Exchange Act") to permit Sulzer, any of its subsidiaries or subsidiary undertakings and any advisor, broker or financial institution acting as an agent or for the account or benefit of Sulzer (the "Prospective Purchasers") to purchase or arrange for the purchase of Bodycote Shares outside the United States other than pursuant to the Offer as described in this letter.

Although Sulzer is currently considering implementing the Offer by way of a cash tender offer, it may elect to implement the Offer by way of a scheme of arrangement (which is a court-based statutory procedure pursuant to the laws of England and Wales whereby Bodycote would request its shareholders to approve in a court-convened and general meeting various resolutions resulting in, among other things, the cancellation of the Bodycote Shares and the payment of the cash consideration to the holders of the Bodycote Shares).

In connection with the Offer, we are U.S. counsel to Sulzer and Slaughter and May is U.K. counsel to Sulzer. The descriptions in this letter of U.K. law are based on discussions with Slaughter and May.

Background

Sulzer. Sulzer operates in the machinery and equipment as well as the surfacing technology business. Sulzer operates in more than 120 locations and employs approximately 10,000 people worldwide. For the fiscal year ended December 31, 2006, Sulzer reported sales of approximately CHF 2,801.7 million, net income of approximately CHF 221.4 million and net assets of approximately CHF 1,544.3 million.

Sulzer is headquartered in Winterthur, Switzerland and is a "foreign private issuer" as defined in Rule 3b-4(c) under the Exchange Act. According to its latest report (dated December 31, 2005), Sulzer's issued and listed voting share capital consisted of 3,638,030 shares with a par value of CHF 0.03 per share ("**Sulzer Ordinary Shares**"). Each Sulzer Ordinary Share carries one vote at shareholder meetings. Sulzer has no class of securities registered with the Commission pursuant to Section 12(b) of the Exchange Act or any securities listed on a U.S. national securities exchange, nor is Sulzer, or has it ever been, subject to the periodic reporting requirements of the Exchange Act. Sulzer Ordinary Shares are traded on the SWX Swiss Exchange, which is the principal trading market for Sulzer Ordinary Shares.

Bodycote. Bodycote is a provider of specialist testing and thermal processing services, heat treatments, hot isostatic pressing, metallurgical coatings and testing services.

Bodycote is headquartered in Cheshire, England and is a "foreign private issuer" as defined in Rule 3b-4(c) under the Exchange Act. In Bodycote's notification to the U.K. market on December 20, 2006 (its most recent notification), Bodycote stated that its share capital consisted of 322,170,735 ordinary shares with a nominal value of 10 pence per share. Bodycote Shares are admitted to the Official List of the United Kingdom Listing Authority ("**UKLA**") and trade on the London Stock Exchange ("**LSE**"). Bodycote has no class of securities registered under Section 12 of the Exchange Act or any securities listed on a U.S. national securities exchange, and, to the best of our knowledge, Bodycote is not, nor has it ever been, subject to the periodic reporting requirements of the Exchange Act.

Sulzer, either directly or indirectly, has acquired Bodycote Shares in open market transactions and as of March 1, 2007 owned just under 1% of the outstanding Bodycote Shares.

Qualification for Tier II Relief. In conducting the Offer on the terms described in this letter, Sulzer currently expects to be able to rely on Rule 14d-1(d) under the Exchange Act, which provides exemptive relief from otherwise applicable rules to persons conducting a tender offer under certain conditions (“Tier II Relief”). In order for an offer to qualify for Tier II Relief, (i) the subject company must be a foreign private issuer as defined in Rule 3b-4 under the Exchange Act and not an investment company, (ii) no more than 40% of the securities of the subject company sought in the offer may be held by holders who are resident in the United States and (iii) the offeror must comply, subject to any applicable exemptions, with all applicable U.S. tender offer rules and regulations.

Pursuant to Rule 14d-1, the issuer of the subject securities will be presumed to be a foreign private issuer and U.S. holders will be presumed to hold 40% or less of such outstanding securities unless: (i) the tender offer is made pursuant to an agreement with an issuer of the subject securities; (ii) the aggregate trading volume of the subject class of securities on all national securities exchanges in the United States, over the 12-calendar-month period ending 30 days before commencement of the offer, exceeds 40%; (iii) the most recent annual report or annual information filed or submitted by the issuer with securities regulators of its home jurisdiction or with the Commission indicates that U.S. holders hold more than 40% of the outstanding subject class of securities; or (iv) the bidder knows or has reason to know that the level of U.S. ownership exceeds 40%.

If Sulzer decides to commence an Offer, a determination will be made under the applicable rules and regulations as to whether such Offer is made pursuant to an agreement with Bodycote. As noted above, Bodycote Ordinary Shares are not listed on any U.S. national securities exchange and, based on publicly available information, Sulzer currently does not know or have any reason to know that the level of U.S. ownership of Bodycote Shares exceeds 40%. In addition, on the basis of such publicly available information, Sulzer believes that U.S. beneficial holders hold less than 40% of the Bodycote Shares. More particularly, based on the most recent regulatory filings and other publicly available information in the United Kingdom, Sulzer estimates that U.S. holders owned approximately 59.5 million Bodycote Shares, which constitute approximately 20.5% of the total outstanding Bodycote Shares as of the date of such available information (assuming the currency of the source information). Such percentage calculation takes into account the exclusion of one holder that has reported aggregate ownership of approximately 10.0% (as of December 21, 2006). It also assumes that the shareholders shown on Bodycote’s share register with U.S. addresses are all holding for U.S. residents. On the basis of the foregoing, Sulzer intends to make the Offer in reliance on Tier II pursuant to Rule 14d-1(d) under the Exchange Act. If the Offer is made in agreement with Bodycote, Sulzer will perform the required analysis to determine whether it qualifies for relief under Rule 14d-1(c) or Rule 14d-1(d) under the Exchange Act.

Proposed Offer Structure

The Offer. As indicated above, it has not yet been determined whether the Offer will be made. Assuming such an Offer is made, it is currently expected that it will be made by Sulzer (or a wholly-owned subsidiary thereof) (the "**Offeror**") and will consist of all cash. It is contemplated that a loan note alternative may be made available to certain non-U.S. holders of Bodycote Shares (as described further below). It is expected that the Offer will be structured as a single offer made concurrently in the United Kingdom, the United States and certain other jurisdictions where the Offer may be legally extended.

The Offer will be structured to comply with (i) the rules and regulations of the UKLA and the LSE, (ii) the City Code on Takeovers and Mergers of the United Kingdom (the "**City Code**") and (iii) except as otherwise requested herein or at a later date, Section 14(e) of the Exchange Act (including Regulation 14E promulgated thereunder) as they apply to offers that satisfy the conditions of Rule 14d-1(d)(1). The Offer is not subject to Section 14(d) of the Exchange Act (or Regulation 14D promulgated thereunder) since Bodycote does not have any class of securities registered under Section 12 of the Exchange Act or listed on a U.S. national securities exchange. The offer document (the "**Offer Document**") used in connection with the Offer will be prepared in compliance with the applicable rules and regulations of the UKLA and the LSE and with the City Code and the Exchange Act.

In such case, the Offer Document would be mailed to all holders of record of Bodycote Shares in the United Kingdom, the United States and certain other jurisdictions where the Offer may be legally extended within 28 calendar days of the date the Offer is announced, as required by Rule 30.1 of the City Code, or such later date as to which the Panel on Takeovers and Mergers (the "**Panel**"), which administers the City Code, may agree. Pursuant to Rule 14e-1(a) under the Exchange Act, the Offer will remain open for acceptances for not less than 20 U.S. business days from the mailing of the Offer Document and the Offer can be extended for such additional period or periods as may be (i) determined by the Offeror and (ii) required or necessary to comply in this respect with Section 14(e) of the Exchange Act and Regulation 14E promulgated thereunder or the City Code, but not while the Offer remains conditional as to the minimum level of acceptance beyond midnight on the 60th calendar day after mailing or such later date as to which the Panel, which administers the City Code, may agree.

Once the Offer becomes or has been declared unconditional as to the minimum level of acceptance, all conditions to the Offer must be satisfied or, where permissible, waived pursuant to Rule 31.7 of the City Code not later than 21 days after the date on which the Offer is declared unconditional as to the level of acceptance, whereupon that Offer will be wholly unconditional (the "**Initial Offer Period**") and the Offeror will accept all Bodycote Shares that have by that

time been validly tendered in acceptance of the Offer and will, in accordance with the City Code, pay for all such accepted Bodycote Shares within 14 calendar days after the Initial Offer Period.

If the Offer becomes or is declared wholly unconditional as to the level of acceptance, the Offer must, in order to comply with Rule 31.4 of the City Code, remain open for acceptance for at least 14 calendar days following the date on which it would otherwise have expired and may remain open for such longer period as the Offeror deems appropriate (the "**Subsequent Offer Period**"). At least 14 calendar days' notice must be given before termination of the Subsequent Offer Period if the announcement of that period stated that the Offer would remain open until further notice. An institution operating in the United Kingdom will act as the U.K. receiving agent to receive tenders of Bodycote Shares pursuant to the Offer. If the Offer has not been declared unconditional as to acceptances 42 calendar days after publication of the Offer Document and in certain other limited circumstances, Bodycote shareholders who have accepted the Offer will be entitled to withdraw their acceptance. Otherwise, Bodycote shareholders would not be entitled to withdraw their acceptance.

The Offer will be subject to a minimum level of acceptance condition, regulatory approvals and various other conditions which generally would be customary for U.K. offers of this type.

Loan Note Alternative. If made available, Bodycote shareholders (other than U.S. shareholders and certain other overseas shareholders) who validly accept the Offer may be able to elect to receive loan notes ("**Loan Notes**") instead of some or all of the cash to which they would otherwise become entitled under the terms of the Offer. Loan Notes can provide certain tax advantages to U.K. taxpayers. Such tax advantages are not available to U.S. taxpayers and Loan Notes will not be available to U.S. shareholders. The Loan Notes will not be listed on any organized securities market and the offering of Loan Notes will not be registered under the Securities Act of 1933, as amended.

Purchases Outside of the Offer and Rule 14e-5

In the United Kingdom, purchases of a target's securities by a bidder or a person acting for the account or benefit of the bidder outside an offer are permitted, subject to certain limitations, and such purchases are common in connection with offers for U.K. companies. Under the City Code, Sulzer and its advisors and brokers are permitted to purchase Bodycote Shares in the open market or otherwise prior to and during the conduct of, but outside, the Offer, subject to certain limitations, including as to price (as described below).

Subject to certain exceptions, Rule 14e-5 prohibits a "covered person" from directly or indirectly purchasing or arranging to purchase any securities to be acquired in a tender offer for equity securities or any securities immediately

convertible into, exchangeable for or exercisable for such securities, except as part of the tender offer. This prohibition applies from the time the offer is publicly announced until it expires. Rule 14e-5 defines a "covered person" as (i) the offeror, its dealer-managers, and any of their respective affiliates, (ii) any advisors of the foregoing whose compensation is dependent on the completion of the offer and (iii) any person acting in concert either directly or indirectly with any of the foregoing.

Pursuant to the City Code, a potential acquirer may publish a Rule 2.4 announcement (a "**Possible Bid Announcement**") that it is considering an offer. Sulzer has published such an announcement on March 2, 2007. However, such an announcement does not obligate a bidder to make a bid or constitute a bid under the City Code. Only upon the announcement of a firm intention to make a bid under Rule 2.5 of the City Code is a bidder obligated to proceed with a bid under the City Code. The Prospective Purchasers want to be in a position to purchase the Bodycote Shares at any time they are permitted to do so under the City Code and other applicable UK rules and regulations. Purchases of Bodycote Shares by the Prospective Purchasers outside of the Offer would not fall within any of the excepted activities specifically outlined in Rule 14e-5. Accordingly in the absence of exemptive relief, such purchases would be prohibited after the announcement of the Offer.

The Commission has enumerated certain factors that it considers important in ruling on a Rule 14e-5 exemption request, including (i) the degree of ownership of the target by U.S. holders, (ii) whether the offer will be made to U.S. holders on an equal basis to non-U.S. holders, (iii) whether the consideration will be cash or securities, (iv) the nature of the foreign regulation to which the offer is subject and (v) whether the principal trading market for the target's securities is outside the United States.

In the context of the Offer, assuming it is made, we believe that (i) U.S. persons beneficially own more than 10% and less than 40% of the Bodycote Shares, which is consistent with the level of U.S. shareholdings noted in prior letters requesting relief from Rule 14e-5,¹ (ii) the Offer is for all the outstanding Bodycote Shares, (iii) the Offer will be made on the same basis to U.S. and non-U.S. holders of Bodycote Shares (with the exception of the offer of Loan Notes to certain non-U.S. Bodycote shareholders) (iv) the consideration will consist entirely of cash (with the exception of the possible offer of Loan Notes to certain non-U.S. Bodycote shareholders), (v) the Panel will have primary regulatory

¹ See, e.g., Consortium bid for Associated British Ports Holdings plc (June 8, 2006); Companhia Siderurgica Nacional for Corus Group plc (December 1, 2006); AstraZeneca PLC for Cambridge Antibody Technology Group plc (May 23, 2006); United Technologies for Kidde plc (December 15, 2004); UCB S.A. for Celltech Group plc (May 19, 2004); Celltech Group plc for Oxford GlycoSciences plc (March 3, 2003); and RWE Aktiengesellschaft for Innogy Holdings plc (March 22, 2002).

authority over the Offer and it will be fully regulated under the City Code and (vi) the principal trading market for the target's securities is outside the United States on the LSE.

Rules 6.1 and 6.2 of the City Code provide protections similar to those provided by Rule 14e-5, making exemptive relief appropriate in the circumstances of the Offer, by requiring that the price paid in the Offer be increased to the level of any higher purchase price for the Bodycote Shares outside the Offer. In addition, under Rule 8.1 of the City Code, any purchases outside the Offer by any party to the transaction (including the offeror, any advisor, broker or other financial institution acting as its agent) are required to be disclosed on a next-day basis to a regulatory information service and the Panel and this information is publicly available on the Regulatory News Service of the LSE which can be accessed on the LSE's website: www.londonstockexchange.com. Disclosures of these purchases attract significant publicity by their very nature and they are disseminated on dealers' trading screens throughout the London market.

Jurisdictional Predicate. Please note that, in our view, there are serious doubts as to whether the jurisdictional predicate for the application of the Exchange Act exists, namely that there be a purchase of a security "by use of the mails or by any means or instrumentality of interstate commerce or of any facility of a national securities exchange", would be satisfied if the Prospective Purchasers made purchases of, or arrangements to purchase, Bodycote Shares outside of the United States. We nonetheless apply, on behalf of the Prospective Purchasers, for exemptive relief for such purchases, or arrangements to purchase, from the provisions of Rule 14e-5, on the conditions set forth below. We have been requested by Sulzer to emphasize that this letter does not reflect an admission that Rule 14e-5 would apply to such purchases of Bodycote Shares outside the United States in the absence of such exemptive relief.

Irrevocable Undertakings

Certain institutional shareholders as well as the directors of Bodycote may be asked to, as is typical in U.K. takeovers, undertake irrevocably to accept the Offer in respect of their holdings of Bodycote Shares. No additional compensation will be paid to these shareholders and they will receive their offer consideration at the same time as the other Bodycote shareholders that accept the Offer if any. If given, certain of the irrevocable undertakings may lapse if a competing offer is made during the pendency of the Offer.

Under U.K. market practice, an irrevocable undertaking is an agreement of a shareholder entered into prior to the offer to accept an offer when made and, in some cases, to not accept a competing offer during the pendency of the first offer. An irrevocable undertaking is not treated by the City Code as a purchase, and the City Code permits bidders to enter into irrevocable undertakings at any time, subject to certain limitations. We note for emphasis that shares subject to an

irrevocable undertaking are purchased in the tender offer and, consequently, count towards satisfying the minimum acceptance condition under the City Code. Acceptances of the Offer in respect of shares which are the subject of irrevocable undertakings represent tenders are subject to both the terms and conditions of the Offer and the City Code. Accordingly, we are not requesting exemptive relief from Rule 14e-5 with respect to the entering into of irrevocable undertakings.²

Requested Relief

Based on the foregoing, we respectfully request relief from Rule 14e-5 under the Exchange Act in order to permit the Prospective Purchasers to purchase or arrange to purchase Bodycote Shares outside of the Offer. The foregoing request for exemptive relief will be subject to the following conditions:

- (a) no purchase or arrangements to purchase Bodycote Shares, otherwise than pursuant to the Offer, will be made in the United States;
- (b) disclosure of the possibility of such purchases will be included prominently in the Offer Document together with disclosure of the manner in which any such purchases are required to be publicly disclosed;
- (c) the Prospective Purchasers shall disclose in the United States information regarding purchases made outside the Offer to the extent such information is made public in the U.K. pursuant to the City Code;
- (d) the Offer is subject to English law and the City Code which requires that the price paid in the Offer be increased to the level of any higher price paid for Bodycote Shares outside the Offer;
- (e) the Prospective Purchasers shall comply with the applicable requirements in the U.K., including the City Code and the rules and regulations of the UKLA and the LSE;
- (f) the Prospective Purchasers shall provide to the Division of Market Regulation, upon request, a daily time-sequenced schedule of all purchases of Bodycote Shares made by any of them during the Offer, on a transaction-by-transaction basis, including (i) size, broker (if any), time of execution, and price of purchase; and (ii) if not executed on the LSE, the exchange, quotation system, or other facility through which the purchase occurred;

² See, e.g., Companhia Siderurgica Nacional for Corus Group plc (December 1, 2006); AstraZeneca PLC for Cambridge Antibody Technology Group plc (May 23, 2006); United Technologies for Kidde plc (December 15, 2004); UCB S.A. for Celltech Group plc (May 19, 2004); Celltech Group plc for Oxford GlycoSciences plc (March 3, 2003); and RWE Aktiengesellschaft for Innogy Holdings plc (March 22, 2002).

(g) upon request of the Division of Market Regulation, the Prospective Purchasers shall transmit the information specified in (f)(i) and (f)(ii) above to the Division of Market Regulation at its offices in Washington, D.C. within 30 days of its request;

(h) the Prospective Purchasers shall retain all documents and other information required to be maintained pursuant to this exemption for a period of not less than two years from the date of the termination of the Offer;

(i) representatives of the Prospective Purchasers shall be made available (in person at the offices of the Division of Market Regulation in Washington, D.C. or by telephone) to respond to inquiries of the Division of Market Regulation relating to such records; and

(j) except as otherwise exempted herein, the Prospective Purchasers shall comply with Rule 14e-5.

We believe the relief requested herein under Rule 14e-5 is consistent with the relief granted by the Commission in, among others, the following no-action letters: Consortium bid for Associated British Ports Holdings plc (June 8, 2006); Companhia Siderurgica Nacional for Corus Group plc (December 1, 2006); The Nasdaq Stock Market, Inc. for the London Stock Exchange Group plc (November 20, 2006); AstraZeneca PLC for Cambridge Antibody Technology Group plc (May 23, 2006); Axel Springer AG Offer for ProSiebenSat. 1 Media AG (Sept. 12, 2005); and United Technologies Corporation for Kidde plc (December 15, 2004).

Finally, we note the existence of the Memorandum of Understanding on Exchange of Information between the Commission and the U.K. Department of Trade and Industry in Matters Relating to Securities and the U.S. Commodity Futures Trading Commission and the U.K. Department of Trade and Industry in Matters Relating to Futures dated September 25, 1991.

* * *


James Brigagliano

10

March 2, 2007

On behalf of Sulzer, we respectfully request that the Commission issue the requested exemptive relief and confirmation as soon as practicable. If you require any further information or have any questions, please contact me at 011-44-20-7418-1386 or by e-mail at jeffrey.oakes@dpw.com.

Very truly yours,



Jeffrey M. Oakes

Cc: Racquel L. Russell
Matthew B. Landon
Division of Market Regulation
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549

Simon Phillips
Slaughter and May
One Bunhill Row
London EC1Y 8YY
United Kingdom